Ochoa-Parra KA, Jiménez-Rodríguez MJ, Arias-Constantino JM, Gurrola-Castillo A, Gómez-Maqueo-Chew A, Ornelas-Aguirre JM

Language: Spanish
References: 17
Page: 14-19
PDF size: 229.66 Kb.

ABSTRACT

Introduction: Immunotherapy has been used for a long time to improve the survival of the renal graft. Thymoglobulin is one of the most used agents. In Mexico, there are few studies on this subject. Objective: To evaluate the success of the use of thymoglobulin as induction therapy and the complications observed in the first year after renal transplantation in a third level care center in northwestern Mexico. Material and methods: Simple and retrospective cross-sectional study in 160 patients transplanted from 2011 to 2016, in all cases thymoglobulin was used as induction therapy. From the clinical files, variables prior to transplantation and follow-up during the first year were reviewed. The information was analyzed with descriptive and inferential statistics. An odds ratio calculation was used to evaluate the risk of complications and failure in therapy. A value of p equal to or less than 0.05 was considered statistically significant. Results: The function of the transplanted graft was successful in 92% of the transplanted cases in relation to serum creatinine levels (p = 0.0001). Renal rejection during the first year occurred in 18% (OR = 0.37, p = 0.03), with the acute type being the most common in 14% (OR = 0.37, p = 0.04). The most common complications were infectious (OR = 0.82, p = 0.60). Discussion: Our results are consistent with that reported in the literature in relation to success in graft survival greater than 95% in those patients managed with thymoglobulin induction during the first year of follow-up.

REFERENCES

1. Lastirí HS. Enfermedad renal crónica en México: una política nacional todavía pendiente. En: Tamayo OJ, Lastiri QH. Academia Nacional de Medicina de México. La enfermedad renal crónica en México. Hacia una política nacional para enfrentarla. México: Intersistemas; 2016. p. 1-16.

2. García GG, Harden P, Chapman J. El papel global del trasplante renal. Nefrología. 2012; 32 (1):1-6.

3. Renjel CF. Trasplante renal: una mejor alternativa para los nefrópatas crónicos. Rev Cient Cienc Med. 2010; 13 (1): 25-30.

4. Starzl TE, Marchioro TL, Hutchinson A et al. The clinical use of antilymphocyte globulin in renal homotransplantations. Transplantation. 1967; 5 (4): 1100-1105.

5. Moreso F, Hernández D. ¿Ha mejorado la supervivencia del injerto tras el trasplante renal en la era de la moderna inmunosupresión? Nefrología. 2013; 33 (1): 14-26.

6. Aguirre-Mendoza FM, González-González AF, Paz-Solís P, Bazán-Borges AF, Portilla-Flores VH, Ramírez-Sáenz F. Inmunosupresión de inducción en trasplante renal alogénico. Evaluación de resultados. Rev Hosp Jua Mex. 2008; 75 (3): 183-189.

7. Hricik DE. Transplant immunology and immunosuppression: core curriculum 2015. Am J Kidney Dis. 2015; 65 (6): 956-966.

8. Vega-Rojano L, Soto-Miranda E, Budar-Fernández LF, Moreno-Ley PI, Martinez-Mier G. Experiencia mexicana con el uso de terapia de inducción con timoglobulina en trasplante renal. Revisión global de la literatura y análisis de sus resultados. Rev Mex Traspl. 2017; 6 (2): 67-74.

9. Laftavi MR, Alnimri M, Weber-Shrikant E, Kohli R, Said M, Patel S et al. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up. Transplant Proc. 2011; 43 (2): 458-461.

10. Noël C, Abramowicz D, Durand D, Mourad G, Lang P, Kessler M et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal trasplant recipients. J Am Soc Nephrol. 2009; 20: 1385-1392.

11. Requiao-Moura LR, Tonato EJ, Arruda-Ferraz E et al. Immunological induction with thymoglobulin: reduction in the number of doses in renal transplant from deceased donor. Einstein. 2011; 9 (1 Pt 1): 56-65.

12. Zaragoza-Salas TA, Rogel-Rodríguez JF, Ojeda-Cervantes M, Racher-Chávez A, González-Toledo R, Noriega-Salas AL et al. Incidencia de rechazo y de infecciones en pacientes trasplantados de riñón de donador vivo relacionado y cadavérico utilizando dosis menor de 5 mg/kg de timoglobuina, en la terapia de inmunosupresión en el Centro Médico “Lic. Adolfo López Mateos” de Toluca. Rev Mex Traspl. 2015; 4 (1): 7-12.

13. Torres-González M, Solís-Vargas E, Cortés-Sanabria L, Santiago-Pedroza O, Gómez-Navarro B. Inducción con timoglobulina versus antagonistas del receptor IL-2 (IL2-RA) en receptores renales de donador de muerte encefálica (DME): supervivencia del paciente y rechazo del injerto a un año. Rev Mex Traspl. 2015; 4 (S1): S122.

14. Martínez-Mier G, Moreno-Ley PI, Soto-Miranda E, Méndez-López MT, Buddar-Fernández L, Aguilar-Sandoval E et al. Inducción con timoglobulina en receptores de trasplante renal de donante vivo: experiencia de un centro mexicano. Rev Mex Traspl. 2016; 5 (S1): S39.

15. Hardinger KL, Schnitzler MA, Koch MJ, Labile E, Stirnemann PM, Miller B et al. Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience. Transplantation. 2006; 81 (9): 1285-1289.

16. Padiyar A, Augustine JJ, Hricik DE. Induction antibody therapy in kidney transplantation. Am J Kidney Dis. 2009; 54 (5): 935-944.

17. Costa de Oliveira CM, Morais-Gomes D, Reuber C et al. Deceased kidney transplantation with thymoglobulin versus anti-IL2R monoclonal antibody induction. A paired kidney analysis. JBT J Bras Transpl. 2011; 14: 1495-1540.